Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

Weight loss on Ozempic is linked to major drops in disease risk

People who lost the most weight on Ozempic saw huge health benefits

Science Daily1 min readAI-assisted summary
Editorial illustration for People who lost the most weight on Ozempic saw huge health benefits
Editorial illustration

Summary

Drugs like Ozempic, Wegovy, Mounjaro, and Saxenda have made headlines for helping people shed pounds. But recent research shows that successfully losing weight on these medications comes with profound medical benefits. Patients who lost a significant amount of weight saw a sharp drop in their risk for serious conditions, specifically kidney disease and sleep apnea, a disorder where a person's breathing repeatedly stops and starts during sleep.

On the other hand, the outcomes were concerning for patients who actually gained weight while taking these medications. This group faced a higher risk of developing severe complications related to obesity. Heart failure was a particularly prominent risk for those who gained weight despite the medical intervention.

A major hurdle to seeing these positive health results is simply staying on the medication. The researchers noted that a large number of patients quit taking the drugs within their first year. While the overall findings are compelling, it is important to view them with a bit of caution for now. The current data lacks details on the exact number of participants, their specific backgrounds, and the precise mathematical changes in their health risks.

Why it matters.

This research cements the idea that these prescriptions are not just lifestyle treatments, but vital interventions for chronic illness. Lowering the rates of kidney disease and heart failure could eventually save healthcare systems massive amounts of money and keep countless patients out of emergency rooms.

However, the high rate of people quitting the medication within a year is a critical warning sign for the medical community. Whether patients are stopping because of uncomfortable side effects, high out-of-pocket costs, or drug shortages, the long-term benefits of these treatments will be lost if people cannot stick with them. The healthcare industry must find ways to support patients through that crucial first year to turn these early promises into lasting public health victories.

From the source

The story in numbers.

Weight-loss medications analyzed
4
Timeframe within which many patients discontinued medication
1 year
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗